Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2012. The report details a specific corporate action regarding share repurchases executed on June 7, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Purchased: 1,700,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,448.5 pence per share; lowest price paid was 1,425.5 pence per share.
- Treasury Holdings (Settled): 452,457,927 shares, representing 8.28% of total issued share capital.
- Treasury Holdings (Including Unsettled): 457,957,927 shares, representing 9.14% of current total voting rights.
- Shares in Issue (Excluding Treasury): 5,012,567,903 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,700,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.14% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (452,457,927 settled) against the company's latest capital structure.
- Confirm the calculation of total voting rights (9.14% held in Treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (5,012,567,903 shares in issue).
- Review the price range paid (1,425.5 to 1,448.5 pence) against market prices on June 7, 2012.